Asunto(s)
Dermatitis Herpetiforme , Nivolumab , Humanos , Nivolumab/efectos adversos , Dermatitis Herpetiforme/inducido químicamente , Masculino , Antineoplásicos Inmunológicos/efectos adversos , Erupciones por Medicamentos/etiología , Erupciones por Medicamentos/patología , Femenino , Prurito/inducido químicamenteAsunto(s)
Melanoma , Neoplasias Cutáneas , Humanos , Melanoma/tratamiento farmacológico , Melanoma/genética , Nivolumab/uso terapéutico , Ipilimumab/uso terapéutico , Proteínas Proto-Oncogénicas B-raf/genética , Neoplasias Cutáneas/tratamiento farmacológico , Neoplasias Cutáneas/genética , Francia , Protocolos de Quimioterapia Combinada AntineoplásicaRESUMEN
BACKGROUND: Lymphomatoid papulosis (LyP) type D (LyP D) and type E (LyP E) have recently been described in small series of cases or isolated case reports. AIM: To further describe the clinical and histological features of LyP D and E based on a retrospective multicentre study. METHODS: The clinical and histopathological features of 29 patients with an initial diagnosis of LyP D or LyP E were retrospectively assessed using standardized forms. RESULTS: After exclusion of 5 cases, 24 patients (14 LyP D, 10 LyP E) were enrolled in the study. The median follow-up was 2.5 years (range 1 month to 13 years). LyP D was characterized by multiple recurrent self-regressing small papules that developed central erosion or necrosis, whereas LyP E presented as papulonodular lesions that rapidly evolved into necrotic eschar-like lesions > 10 mm in size. Epidermal changes were more frequent in LyP D, whereas dermal infiltrates were deeper in LyP E. Anaplastic cytology was rare and the DUSP22 rearrangement was never observed. Two patients (8%) had an associated cutaneous lymphoma. CONCLUSION: LyP D and E have distinct clinical findings and may be associated with other cutaneous lymphomas.
Asunto(s)
Papulosis Linfomatoide/clasificación , Papulosis Linfomatoide/patología , Neoplasias Cutáneas/clasificación , Neoplasias Cutáneas/patología , Adulto , Edad de Inicio , Femenino , Estudios de Seguimiento , Reordenamiento Génico de la Cadena gamma de los Receptores de Antígenos de los Linfocitos T , Humanos , Hiperplasia , Inmunofenotipificación , Papulosis Linfomatoide/genética , Masculino , Persona de Mediana Edad , Necrosis , Recurrencia Local de Neoplasia/patología , Estudios Retrospectivos , Neoplasias Cutáneas/genética , Úlcera Cutánea/patologíaRESUMEN
INTRODUCTION: Simulation in healthcare is a rapidly developing teaching method in the training of technical procedures. It is also used to enable caregivers to learn how to inform patients of serious illness and complex health status. However, its use is not widespread in the field of dermatology. This study investigated the utility of simulation as regards disclosing melanoma diagnosis, taking resident physician satisfaction as a primary endpoint. MATERIALS AND METHODS: Fifteen dermatology residents were recruited as trainees. Four scenarios were allocated based on length of residency. An introductory briefing was held prior to the training sessions. Debriefing took place on completion of the diagnosis disclosure consultation. The participants completed questionnaires after the simulation session, after debriefing, and 3 months after the simulation session. The primary endpoint was usefulness of the session felt by trainees several months after the simulation. RESULTS: The majority of participants (93.3%) thought the session helped with stress management, improved their attitude and control over their reaction (86.6%), and improved their communication skills (100%). They rated the usefulness of the simulation at 7.79/10 on average (range: 5-10). DISCUSSION: According to our findings the resident physicians involved, particularly those with the least experience, were satisfied with this type of learning technique. Any difficulties encountered by these residents were brought to light and addressed during debriefing. CONCLUSION: There would appear to be real benefits to be reaped from simulation, whatever the stage of medical training at which it takes place. Simulation should become an increasingly important part of contemporary pregraduate specialty programs.
Asunto(s)
Dermatología , Internado y Residencia , Competencia Clínica , Comunicación , Humanos , Encuestas y CuestionariosAsunto(s)
Acrodermatitis/inmunología , Anticuerpos Antivirales/inmunología , Infecciones por Coronavirus/complicaciones , Erupciones Liquenoides/inmunología , Neumonía Viral/complicaciones , Síndrome Respiratorio Agudo Grave/inmunología , Acrodermatitis/etiología , Acrodermatitis/patología , Adulto , Biopsia con Aguja , COVID-19 , Estudios de Cohortes , Infecciones por Coronavirus/diagnóstico , Femenino , Humanos , Inmunohistoquímica , Erupciones Liquenoides/etiología , Erupciones Liquenoides/patología , Masculino , Persona de Mediana Edad , Pandemias , Neumonía Viral/diagnóstico , Pronóstico , Síndrome Respiratorio Agudo Grave/complicaciones , Síndrome Respiratorio Agudo Grave/diagnósticoAsunto(s)
Cicatriz/inmunología , Enfermedad de Crohn/tratamiento farmacológico , Dermatosis Facial/inmunología , Enfermedades Nasales/inmunología , Inhibidores del Factor de Necrosis Tumoral/efectos adversos , Adulto , Cicatriz/inducido químicamente , Cicatriz/diagnóstico , Enfermedad de Crohn/inmunología , Dermatosis Facial/inducido químicamente , Dermatosis Facial/complicaciones , Dermatosis Facial/diagnóstico , Femenino , Humanos , Masculino , Persona de Mediana Edad , Enfermedades Nasales/inducido químicamente , Enfermedades Nasales/complicaciones , Enfermedades Nasales/diagnósticoAsunto(s)
Productos Biológicos/efectos adversos , Linfoma de Células B/epidemiología , Linfoma Cutáneo de Células T/epidemiología , Neoplasias Cutáneas/epidemiología , Biopsia , Bases de Datos Factuales/estadística & datos numéricos , Estudios de Seguimiento , Francia/epidemiología , Humanos , Linfoma de Células B/inducido químicamente , Linfoma de Células B/diagnóstico , Linfoma de Células B/patología , Linfoma Cutáneo de Células T/inducido químicamente , Linfoma Cutáneo de Células T/diagnóstico , Linfoma Cutáneo de Células T/patología , Farmacovigilancia , Pitiriasis Rubra Pilaris/tratamiento farmacológico , Psoriasis/tratamiento farmacológico , Estudios Retrospectivos , Piel/patología , Neoplasias Cutáneas/inducido químicamente , Neoplasias Cutáneas/diagnóstico , Neoplasias Cutáneas/patologíaAsunto(s)
Micosis Fungoide/diagnóstico , Neoplasias Cutáneas/diagnóstico , Enfermedades de la Vulva/etiología , Anciano de 80 o más Años , Femenino , Humanos , Micosis Fungoide/complicaciones , Micosis Fungoide/patología , Neoplasias Cutáneas/complicaciones , Neoplasias Cutáneas/patología , Enfermedades de la Vulva/patologíaRESUMEN
BACKGROUND: Herein, we report a case of systemic cutaneous T-cell lymphoma refractory to standard therapy, the course of which resulted in haplo-identical bone marrow grafting. PATIENTS AND METHODS: A 53-year-old woman consulted for facial erythema with infiltration, keratotic lesions on the trunk, and adenopathies measuring around 1cm on the axilla and inguinal folds. A diagnosis was made of Sézary syndrome (SS), a leukaemic form of epidermotropic cutaneous T-cell lymphoma. After three years of treatment with methotrexate, the patient developed transformed SS with visceral involvement. Given the high risk of relapse and the absence of an HLA-compatible donor, haploidentical bone marrow grafting was performed. The patient was still in complete remission two and a half years later. The disease course was nevertheless marked by the emergence one year after grafting of a Blaschko-distributed lichenoid eruption having histological features consistent with chronic graft-versus-host disease (GVHD); treatment with topical betamethasone proved efficacious. DISCUSSION: To our knowledge, this is the first reported case of haploidentical grafting for systemic and transformed cutaneous T-cell lymphoma. This approach could henceforth represent a therapeutic option for patients requiring an allograft in the absence of compatible donors. The Blaschko-distributed lichenoid lesions attributed to chronic GVHD could be the result of reduced immune tolerance to abnormal embryological clones leading to a T-lymphocyte-mediated inflammatory reaction.
Asunto(s)
Trasplante de Médula Ósea , Linfoma de Células T Periférico/cirugía , Síndrome de Sézary/cirugía , Neoplasias Cutáneas/cirugía , Femenino , Humanos , Persona de Mediana Edad , Trasplante HaploidénticoRESUMEN
BACKGROUND: Identification of myositis-specific autoantibodies (MSAs) for dermatomyositis (DM) could allow the characterization of an antibody-associated clinical phenotype. OBJECTIVE: We sought to define the clinical phenotype of DM and the risk of cancer, interstitial lung disease (ILD) and calcinosis based on MSA. METHODS: A 3.5-year multicentre prospective study of adult DM patients was conducted to determine the clinical phenotype associated with MSAs and the presence of cancer, ILD and calcinosis. RESULTS: MSAs were detected in 47.1% of 117 included patients. Patients with antimelanoma differentiation-associated protein-5 antibodies (13.7%) had significantly more palmar violaceous macules/papules [odds ratio (OR) 9.9], mechanic's hands (OR 8), cutaneous necrosis (OR 3.2), articular involvement (OR 15.2) and a higher risk of ILD (OR 25.3). Patients with antitranscriptional intermediary factor-1 antibodies (11.1%), antinuclear matrix protein-2 antibodies (6.8%) and antiaminoacyl-transfer RNA synthetase (5.1%) had, respectively, significantly more poikiloderma (OR 5.9), calcinosis (OR 9.8) and articular involvement (OR 15.2). Cutaneous necrosis was the only clinical manifestation significantly associated with cancer (OR 3.1). CONCLUSION: Recognition of the adult DM phenotype associated with MSAs would allow more accurate appraisal of the risk of cancer, ILD and calcinosis.
Asunto(s)
Anticuerpos/sangre , Dermatomiositis/sangre , Dermatomiositis/complicaciones , Helicasa Inducida por Interferón IFIH1/inmunología , Neoplasias/complicaciones , Piel/patología , Adenosina Trifosfatasas/inmunología , Adulto , Anciano , Anciano de 80 o más Años , Aminoacil-ARNt Sintetasas/inmunología , Calcinosis/sangre , Calcinosis/complicaciones , Proteínas de Unión al ADN/inmunología , Femenino , Dermatosis de la Mano/sangre , Dermatosis de la Mano/complicaciones , Humanos , Artropatías/sangre , Artropatías/complicaciones , Enfermedades Pulmonares Intersticiales/sangre , Enfermedades Pulmonares Intersticiales/complicaciones , Masculino , Persona de Mediana Edad , Necrosis , Fenotipo , Estudios Prospectivos , Factores de Transcripción/inmunología , Adulto JovenRESUMEN
BACKGROUND: Mastocytosis is characterised by the presence of abnormal quantities of mastocytes in one or more organs. Although it occurs in systemic forms of mastocytosis, isolated skin involvement is the predominant presentation, particularly in children, in the form of more or less extensive though non-systematic lesions. Herein, we report a case of maculopapular cutaneous mastocytosis that is unusual in terms of its metameric topography. PATIENTS AND METHODS: A 16-year-old youth presented with an erythematous maculopapular rash of 18 months' duration and involving pruritic inflammatory episodes strictly localised in segment T8 to the left. The skin biopsy showed a significant increase in the number of dermal mastocytes (CD117+). No KIT mutations were found in the skin lesions nor in the unimpaired skin of the opposite side. Further investigations ruled out systemic mastocytis. DISCUSSION: Herein, we report a case of cutaneous mastocytosis that is unusual in terms of its metameric disposition. There have been only two previous reports of segmental cutaneous mastocytis. The two pathological hypotheses involved precessional dermatitis that renders the skin surface susceptible to homing, and somatic mosaicism (type 1) with local mastocyte proliferation.
Asunto(s)
Mastocitos/patología , Mastocitosis Cutánea/patología , Adolescente , Biopsia , Diagnóstico Diferencial , Humanos , Masculino , Piel/patologíaRESUMEN
BACKGROUND: Circumscribed palmar hypokeratosis (CPH) is a rare skin disease, first described in 2002, associated with sudden localized reduction of the corneal layer. In most cases, it presents as an isolated rounded erythematous palmar lesion on the thenar eminence. We describe the dermoscopic semiology of CPH in 3 cases. PATIENTS AND METHODS: Three patients between the ages of 59 and 72 presented very limited erythematous lesions suggestive of CPH. Dermoscopic examination of these lesions provided similar findings. Biopsy, which was performed in one patient, confirmed the diagnosis of CPH. RESULTS: Two dermoscopic elements of CPH are characteristic: (1) the sides of the lesion have a "stair step" or "geological strata" type of configuration, and the thickness of the different strata varies; (2) the centre of the lesion showed a homogeneous erythematous area with a vascular pattern composed of dotted vessels of the superficial dermis and sometime vascular loops. DISCUSSION: These dermoscopic aspects are characteristic and enable CPH to be differentiated from Bowen's disease or porokeratosis of Mibelli. In Bowen's disease, there is no stair step like aspect to the sides of lesions; further, the centre of the lesion shows glomerular vessels (coiled vessels) and/or globular vessels (small red clods). In porokeratosis, peripheral keratotic "white track" structures comprise a single pigmented channel or a double white line. There is no "stair step" or central vascular pattern. CONCLUSION: The dermoscopic semiology of CPH is highly characteristic and enables differentiation from Bowen's disease and porokeratosis.
Asunto(s)
Dermoscopía , Dermatosis de la Mano/patología , Anciano , Biopsia , Diagnóstico Diferencial , Femenino , Humanos , Persona de Mediana EdadRESUMEN
Metastatic melanomas are highly aggressive and median survival is 6-9months for stage IV patients in the absence of treatment with anti-tumor activity. Dacarbazine is an alkylating agent that has been widely used in the treatment of metastatic melanomas and that could be still used in combination with targeted or immune therapies. Indeed, therapeutic benefits of these treatments in monotherapy are poor and one option to improve them is to combine drugs and/or to better anticipate the individual response to a defined treatment. To our best knowledge and to date, there is no test available to predict the response of a patient to dacarbazine. We show here that examination of melanoma histological sections by infrared micro-spectroscopy reveals the sensitivity of the cancer to dacarbazine. Unsupervised analysis of the FTIR spectra evidences spontaneous and significant clustering of infrared spectra into two groups that match the clinical responsiveness of the patients to dacarbazine used as a first-line treatment. A supervised model resulted in 83% of the patient status (responder/non-responder) being correctly identified. The spectra revealed a key modification in the nature and quantity of lipids in the cells of both groups.
Asunto(s)
Antineoplásicos Alquilantes/uso terapéutico , Dacarbazina/uso terapéutico , Melanoma/diagnóstico , Melanoma/tratamiento farmacológico , Espectroscopía Infrarroja por Transformada de Fourier/métodos , Humanos , Melanoma/química , Melanoma/patología , Modelos Biológicos , Análisis de Componente Principal , Pronóstico , Curva ROCRESUMEN
OBJECTIVE: Pseudoxanthoma elasticum is an inherited metabolic disorder resulting from ABCC6 gene mutations. It is characterized by progressive calcification and fragmentation of elastic fibers in the skin, retina, and the arterial wall. Despite calcium accumulation in the arteries of patients with pseudoxanthoma elasticum, functional consequences remain unknown. In the present study, we investigated arterial structure and function in Abcc6(-/-) mice, a model of the human disease. APPROACH AND RESULTS: Arterial calcium accumulation was evaluated using alizarin red stain and atomic absorption spectrometry. Expression of genes involved in osteochondrogenic differentiation was measured by polymerase chain reaction. Elastic arterial properties were evaluated by carotid echotracking. Vascular reactivity was evaluated using wire and pressure myography and remodeling using histomorphometry. Arterial calcium accumulation was 1.5- to 2-fold higher in Abcc6(-/-) than in wild-type mice. Calcium accumulated locally leading to punctuate pattern. Old Abcc6(-/-) arteries expressed markers of both osteogenic (Runx2, osteopontin) and chondrogenic lineage (Sox9, type II collagen). Abcc6(-/-) arteries displayed slight increase in arterial stiffness and vasoconstrictor tone in vitro tended to be higher in response to phenylephrine and thromboxane A2. Pressure-induced (myogenic) tone was significantly higher in Abcc6(-/-) arteries than in wild type. Arterial blood pressure was not significantly changed in Abcc6(-/-), despite higher variability. CONCLUSIONS: Scattered arterial calcium depositions are probably a result of osteochondrogenic transdifferentiation of vascular cells. Lower elasticity and increased myogenic tone without major changes in agonist-dependent contraction evidenced in aged Abcc6(-/-) mice suggest a reduced control of local blood flow, which in turn may alter vascular homeostasis in the long term.
Asunto(s)
Transportadoras de Casetes de Unión a ATP/deficiencia , Arterias/metabolismo , Calcio/metabolismo , Tejido Elástico/metabolismo , Seudoxantoma Elástico/metabolismo , Calcificación Vascular/metabolismo , Rigidez Vascular , Vasoconstricción , Transportadoras de Casetes de Unión a ATP/genética , Animales , Presión Arterial , Arterias/patología , Arterias/fisiopatología , Biomarcadores/metabolismo , Transdiferenciación Celular , Condrogénesis , Colágeno Tipo II/genética , Colágeno Tipo II/metabolismo , Subunidad alfa 1 del Factor de Unión al Sitio Principal/genética , Subunidad alfa 1 del Factor de Unión al Sitio Principal/metabolismo , Modelos Animales de Enfermedad , Tejido Elástico/patología , Tejido Elástico/fisiopatología , Regulación de la Expresión Génica , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Proteínas Asociadas a Resistencia a Múltiples Medicamentos , Osteogénesis , Osteopontina/genética , Osteopontina/metabolismo , Seudoxantoma Elástico/genética , Seudoxantoma Elástico/patología , Seudoxantoma Elástico/fisiopatología , ARN Mensajero/metabolismo , Flujo Sanguíneo Regional , Factores de Transcripción SOXB1/genética , Factores de Transcripción SOXB1/metabolismo , Calcificación Vascular/genética , Calcificación Vascular/patología , Calcificación Vascular/fisiopatologíaRESUMEN
BACKGROUND: In most patients pseudoxanthoma elasticum (PXE) manifests with yellowish cutaneous papules and dermal elastorrhexis on skin biopsy. In a small number of cases there are no skin manifestations on clinical examination, and establishing a diagnosis of PXE in such patients is challenging. High-frequency ultrasonography (HFUS) may be of use in predicting skin areas that would yield a biopsy specimen positive for elastorrhexis. OBJECTIVES: To describe characteristics of clinically visible PXE skin using HFUS, and to evaluate its relevance for diagnosis. METHODS: HFUS was performed in a cohort of patients with PXE and in controls at a referral centre. HFUS images of PXE skin were compared with those of other conditions. Five operators blind-scored multiple HFUS images of photoprotected or photoexposed skin from patients with PXE and controls. The diagnostic indices (sensitivity, specificity, likelihood ratios, interobserver agreement) were calculated. RESULTS: The HFUS changes considered as diagnostic for PXE were primarily oval homogeneous hypoechogenic areas in the mid-dermis. The size of these areas closely matched the extent of the histological changes. The sensitivity and specificity of the diagnostic items and interobserver agreement were high, particularly in photoprotected skin. Dermal hypoechogenicity in PXE could be related to high hydration of connective tissue due to the presence of glycosaminoglycans despite elastic fibre mineralization. CONCLUSIONS: HFUS provides suggestive images of PXE skin lesions. HFUS should now be studied to determine whether it is a potentially valuable technique for the noninvasive identification of elastorrhexis in patients with PXE in whom skin involvement is clinically minimal or absent.
Asunto(s)
Seudoxantoma Elástico/diagnóstico por imagen , Piel/patología , Adolescente , Anciano , Estudios de Casos y Controles , Femenino , Humanos , Persona de Mediana Edad , Variaciones Dependientes del Observador , Seudoxantoma Elástico/patología , Sensibilidad y Especificidad , Piel/diagnóstico por imagen , Piel/efectos de la radiación , Luz Solar/efectos adversos , Protectores Solares/farmacología , Ultrasonografía , Adulto JovenRESUMEN
BACKGROUND: Ipilimumab is a monoclonal antibody targeting cytotoxic T-lymphocyte antigen 4 (CTLA-4) that allows increased survival and, occasionally, complete remission, in the treatment of metastatic melanoma. The most frequent adverse effects are attributed to dysimmunity. We report the case of a female patient who developed orbital myositis during treatment with ipilimumab. PATIENTS AND METHODS: A woman on ipilimumab for a heel melanoma with mediastinal metastases was referred for evaluation of painful diplopia and proptosis that began three days after the fourth infusion of ipilimumab. The clinical examination disclosed a left abductiondeficit associated with conjunctival hyperaemia and palpebral oedema. Orbital MRI disclosed enlargement of the left lateral rectus, enhancing after contrast. An extensive work-up did not find any evidence for thyroid-related eye disease, as well as other orbital inflammatory processes, orbital cellulitis or orbital metastases. Treatment with high-dose oral steroids resulted in complete clinical recovery within a few days. DISCUSSION: To our knowledge, this is the first clinical report of orbital myositis as an adverse event related to anti-CTLA-4 antibody treatment. Both timing and usual profile of adverse events support the hypothesis that orbital myositis has to be attributed there to ipilimumab. Several dysimmune toxicities were observed with ipilimumab. Ophtalmic toxicity has unusually been described. Most cases were uveitis. Whether immune-related adverse events correlate with clinical response to ipilimumab treatment remains to be determined.
Asunto(s)
Anticuerpos Monoclonales/efectos adversos , Antineoplásicos/efectos adversos , Inmunoterapia , Miositis Orbitaria/inducido químicamente , Anciano , Anticuerpos Monoclonales/inmunología , Anticuerpos Monoclonales/uso terapéutico , Antineoplásicos/inmunología , Antineoplásicos/uso terapéutico , Linfocitos T CD4-Positivos/efectos de los fármacos , Antígeno CTLA-4/inmunología , Trombosis del Seno Cavernoso/diagnóstico , Celulitis (Flemón)/diagnóstico , Terapia Combinada , Diagnóstico Diferencial , Diplopía/etiología , Exoftalmia/etiología , Femenino , Enfermedades del Pie/cirugía , Enfermedades del Pie/terapia , Humanos , Ipilimumab , Metástasis Linfática , Melanoma/secundario , Melanoma/cirugía , Melanoma/terapia , Miositis Orbitaria/complicaciones , Miositis Orbitaria/diagnóstico , Miositis Orbitaria/tratamiento farmacológico , Neoplasias Cutáneas/cirugía , Neoplasias Cutáneas/terapiaRESUMEN
BACKGROUND: Annular elastolytic giant-cell granuloma (AEGCG) is a rare form of granulomatous dermatosis characterized by annular plaques with central atrophy and raised erythematous margins and is usually located on the facial and neck areas. It is characterized histologically by loss of elastic fibre and elastophagocytosis. We report a case of AEGCG. CASE REPORT: A 72-year-old man consulted for annular plaques, some of which were atrophic, and papules that had been present for 2 years. The lesions involved sun-exposed and non-sun-exposed skin. The biopsies showed granulomatous infiltrates and discrete elastophagocytosis. After ruling out various differential clinical and histological diagnoses, the patient was diagnosed with AEGCG. DISCUSSION: We report a case of AEGCG. Diagnosis was not easy. The differential diagnoses of this entity were discussed and we ruled out actinic granuloma, sarcoidosis, leprosy, and granuloma annulare. Our patient presented the classical annular variant combined with a papular variant. We report the first case involving response to isotretinoin.